Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.
作者信息
Anderson K E, Girdwood A C, Wilson J A
出版信息
BMJ. 1996 Mar 16;312(7032):702; author reply 704-5. doi: 10.1136/bmj.312.7032.702.
Abstract
摘要
相似文献
1
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.
BMJ. 1996 Mar 16;312(7032):702; author reply 704-5. doi: 10.1136/bmj.312.7032.702.
2
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages.
BMJ. 1996 Mar 16;312(7032):703; author reply 704-5.
3
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
BMJ. 1996 Mar 16;312(7032):702-3; author reply 704-5.
4
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.
BMJ. 1996 Mar 16;312(7032):703-4; author reply 704-5. doi: 10.1136/bmj.312.7032.703b.
5
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used.
BMJ. 1996 Mar 16;312(7032):704; author reply 704-5.
6
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.
BMJ. 1996 Mar 16;312(7032):704-5. doi: 10.1136/bmj.312.7032.704.
7
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality.
BMJ. 1996 Mar 16;312(7032):702; author reply 704-5.
8
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.
BMJ. 1996 Mar 16;312(7032):703; author reply 704-5. doi: 10.1136/bmj.312.7032.703.
9
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
BMJ. 1995 Dec 16;311(7020):1602-7. doi: 10.1136/bmj.311.7020.1602.
10
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
BMJ. 1998 Apr 18;316(7139):1191-6. doi: 10.1136/bmj.316.7139.1191.
引用本文的文献
1
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1997 Aug;63(2):228-34. doi: 10.1136/jnnp.63.2.228.
2
Mortality associated with selegiline in Parkinson's disease. What do the available data mean?
Drug Saf. 1997 May;16(5):289-94. doi: 10.2165/00002018-199716050-00001.
本文引用的文献
1
Selegiline in Parkinson's disease.
BMJ. 1995 Dec 16;311(7020):1583-4. doi: 10.1136/bmj.311.7020.1583.
2
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.
Neurology. 1992 Mar;42(3 Pt 1):541-4. doi: 10.1212/wnl.42.3.541.
Zotero 插件